Search Blog
Categories
May 2018
M T W T F S S
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aceto Corporation of Class Action Lawsuit and Upcoming Deadline – ACET

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Aceto Corporation (“Aceto” or the “Company”) (NASDAQ: ACET) and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and docketed under 18-cv-02437, is on behalf of a class consisting of investors who purchased or otherwise acquired Aceto securities between February 1, 2018, through April 18, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Aceto securities between February 1, 2018, and April 18, 2018, both dates inclusive, you have until June 25, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Aceto Corporation markets, sells, and distributes human health products, pharmaceutical ingredients, and performance chemicals. The Company offers finished dosage form generics, nutritionals, pharmaceutical intermediates, active pharmaceutical ingredients, specialty chemicals, and agricultural protection products.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) due to undisclosed competitive and pricing pressures, Aceto was unlikely to meet the performance metrics the Company provided to its investors as financial guidance; (ii) accordingly, Aceto’s financial guidance was overstated; and (iii) as a result of the foregoing, Aceto’s financial statements and Defendants’ statements about Aceto’s business, operations, and prospects, were materially false and misleading at all relevant times.

On April 18, 2018, after the market closed, Aceto disclosed that “the financial guidance issued on February 1, 2018, should no longer be relied upon,” and suspended “further financial guidance for at least the balance of the fiscal year.” Aceto also disclosed that “the Company anticipates recording non-cash intangible asset impairment charges, including goodwill, in the range of $230 million to $260 million on certain currently marketed and pipeline generic products as a result of continued intense competition and pricing pressures.” Aceto also disclosed the resignation of its Chief Financial Officer, Edward Borkowski, who had joined Aceto just two months earlier.

As a result of the disclosure, Aceto’s stock price fell $4.74 per share, or 64%, to close at $2.66 per share on April 19, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500698

Horace Mann Declares Quarterly Dividend of $0.285

By Horace Mann Educators Corporation

SPRINGFIELD, IL / ACCESSWIRE / May 23, 2018 / Horace Mann Educators Corporation (NYSE: HMN) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.285 per share payable on June 29, 2018, to shareholders of record as of June 14, 2018.

About Horace Mann

Horace Mann is the largest financial services company focused on providing America’s educators and school employees with insurance and retirement solutions. Founded by Educators for Educators® in 1945, the company is headquartered in Springfield, Ill. For more information, visit www.horacemann.com.

Safe Harbor Statement

Statements included in this news release that are not historical in nature are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to certain risks and uncertainties. Horace Mann is not under any obligation to (and expressly disclaims any such obligation to) update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Please refer to the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2018 and the company’s past and future filings and reports filed with the Securities and Exchange Commission for information concerning the important factors that could cause actual results to differ materially from those in forward-looking statements.

Website: https://www.horacemann.com

Contact information:

Heather Wietzel, Vice President, Investor Relations
217-788-5144

SOURCE: Horace Mann Educators Corporation

ReleaseID: 500663

PDCO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Patterson Companies, Inc. and a Lead Plaintiff Deadline of May 29, 2018

By The Law Offices of Vincent Wong

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Minnesota on behalf of investors who purchased Patterson Companies, Inc. (“Patterson”) (NASDAQ: PDCO) securities between June 26, 2015 and February 28, 2018 .

Click here to learn about the case: http://www.wongesq.com/pslra-c/patterson?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Defendants were engaged in a fraudulent and illegal price-fixing conspiracy; (2) the Company’s revenue and earnings were fraudulently inflated by the illegal scheme; (3) the scheme was aimed at prohibiting sales to, and price negotiations by, group purchasing organizations (“GPOs”) that represented small and independent dental practices; (4) as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

If you suffered a loss in Patterson you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/patterson?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 500648

Fawell Calls for End of White House Office of Information and Regulatory Affairs (OIRA)

By Northwest IL 17th Congressional District

GALENA, IL / ACCESSWIRE / May 23, 2018 / Bill Fawell, Congressional Candidate for the 17th Congressional District, outlined the details of his proposed Liberty Act legislation calling for the termination of the White House Office of Information and Regulatory Affairs (OIRA).

”In my proposed Liberty Act, I will be calling for the dissolution of the White House Office of Information and Regulatory Affairs, which has replaced the Congress as the final arbiter for 90% of the laws we Americans live under today,” Fawell declared.

The Office of Information and Regulatory Affairs (OIRA) was created in 1988 to give corporations a say in the growing number of laws created by the many federal agencies chartered during the 1970s and 80s. The OIRA has final say over agency law creation and can recraft said laws without oversight. Only its chairman and vice-chair are identified to the public with staff remaining anonymous. All proceedings are conducted without recording rendering Freedom Of Information Act (FOIA) requests beyond access.

”A parallel government comprised of 10,000 lobbyists spending $3 billion dollars annually has sprung up around the OIRA, a parallel government which corrupts our elections and rules our lives,” Fawell explained. ”This is how billionaires and corporations buy the best laws money can buy without ever going before the United States Congress, the people’s place in our government. It is the well spring of every malady that afflicts America today and nothing in America is going to change until we the people end this extra constitutional agency government that makes 90% of our laws against 90% of the people.”

”My proposed Liberty Act will return all federal public agencies back to the states, and the law making powers of the remaining Independent and Private Agencies back to the legislative process of the Congress where it belongs,” Fawell said in closing.

Go to www.ElectFawell.com to support his campaign and to review his earlier endorsement of what Fawell calls Liberty Legislation: 1) Term Limits, 2) the REINS Act, which restores the powers to make laws back to our Congress and away from federal agencies, and 3) HR 24/S 26, the Federal Reserve Bank Transparency Act and an audit of the Fed; view his explanations on Youtube at https://youtu.be/xpgi8NoX8yg; at Facebook Elect Fawell; on Twitter @WmWFawell; and www.electfawell.com/fawell-blog to check the link to the blog page.

Contact Info For Interviews:

Bill Fawell
815-353-9888
bill@electfawell.com

SOURCE: Northwest IL 17th Congressional District

ReleaseID: 500693

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Overstock.com, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – OSTK

By Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Overstock.com, Inc. (“Overstock”) (NASDAQ: OSTK) between August 3, 2017 and March 26, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Utah. To get more information go to:

http://www.zlk.com/pslra-d/overstock-com-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Overstock’s coin offering was problematic and potentially illegal; and (2) the company’s Medici business was hemorrhaging money. When the true details entered the market, the lawsuit claims that investors suffered damages. On March 1, 2018, Overstock revealed that the Securities and Exchange Commission (“SEC”) had requested information about its initial coin offering. Then, on March 15, 2018, Overstock announced that “the investigation could result in a delay of the tZero security token offering, negative publicity for tZero or us, and may have a material adverse effect on us or on the current and future business ventures of tZero.” Overstock also said that the SEC was examining the advisers at tZero.

If you suffered a loss in Overstock you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 500664

LFIN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Longfin Corp. and a Lead Plaintiff Deadline of June 4, 2018

By The Law Offices of Vincent Wong

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Longfin Corp. (“Longfin”) (NASDAQ: LFIN) securities between December 13, 2017 and April 2, 2018.

Click here to learn about the case: http://www.wongesq.com/pslra-c/longfin-corp?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Longfin had material weaknesses in its operations and internal controls that hindered the Company’s profitability; (ii) Longfin did not meet the requirements for inclusion in Russell indices; and (iii) as a result of the foregoing, the Defendants’ public statements were materially false and misleading at all relevant times.

If you suffered a loss in Longfin you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/longfin-corp?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 500650

SLDB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Solid Biosciences Inc. and a Lead Plaintiff Deadline of May 29, 2018

By The Law Offices of Vincent Wong

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Solid Biosciences Inc. (“Solid Biosciences”) (NASDAQ: SLDB) securities pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018.

Click here to learn about the case: http://www.wongesq.com/pslra-c/solid-biosciences-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Bioscience’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) the company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.

If you suffered a loss in Solid Biosciences you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/solid-biosciences-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 500649

Avalon Announces Updated Resource Estimate and Development Plans for Separation Rapids Lithium Project, Kenora, Ontario

Toronto, Ontario–(Newsfile Corp. – May 23, 2018) – Avalon Advanced Materials Inc. (TSX: AVL) (OTCQX: AVLNF) (“Avalon” or the “Company”) is pleased to announce a mineral resource estimate update for the Separation Rapids lithium deposit which includes results from the 2018 winter drilling program disclosed in the Company’s news release dated April 3, 2018. In this program, four holes extended the known deposit to depth on both its east and west ends, resulting in a 10% increase in overall tonnage. This brings the total Measured and Indicated Resources to 8.405 million tonnes at 1.408% Li2O, with an additional Inferred Resource of 1.791 million tonnes at 1.349% Li2O (as summarized in Table 1 below). The deposit remains open to depth. The new resource estimate will be incorporated into an updated Preliminary Economic Assessment (“PEA”) now in preparation and targeted for completion by June 30, 2018.

Project Development Update

Development has been focused on evaluating several variants on the project model based on the relative proportions of the various potential lithium products. The current model, which will be the basis for the updated PEA, contemplates a staged development approach which begins with a Phase 1 plant capable of initially producing 75,000 tonnes per annum (“tpa”) of lithium mineral concentrate (petalite) for sale as an industrial mineral product to consumers in the glass industry, in addition to a further 40,000 tpa of lepidolite concentrate for sale to lithium chemical producers. Once scaled up, this plant will produce almost 180,000 tpa of lithium mineral concentrate. The plant will also have the potential to produce a feldspar concentrate by-product for other markets.

Phase 2 would involve a demonstration-scale hydrometallurgical pilot plant to begin producing trial quantities of the lithium battery material derivative product (lithium hydroxide or carbonate) for evaluation by potential end-users. Following acceptance of the product in the market, the Company would then proceed with a scale-up of the hydrometallurgical plant in Phase 3 to produce up to 10,000 tpa of lithium battery materials in addition to continuing to serve its other customers with industrial mineral products.

This development model has several potential significant economic benefits that could greatly reduce overall investment risk compared to the model used in the Company’s 2016 PEA that contemplated a relatively large initial capital investment ($450 million) to construct a 14,500 tpa dedicated lithium hydroxide production facility. These benefits include the potential of a relatively low initial CAPEX, (targeting in the range of $50-70 million), early positive cash flow from industrial minerals product sales and flexibility in product design to ensure broad market acceptance before incurring the larger capital investment required to build the Phase 3 hydrometallurgical plant.

Interest in the Company’s lithium mineral (petalite) product from glass industry consumers is high due to its exceptional purity, which is an increasingly important factor in many new high-strength glass formulations. The Company is in advanced discussions with several glass industry customers with a view toward securing the offtake commitments required to finalize the project engineering and plant design and secure project financing.

With the completion of the updated PEA by June 30, 2018 and the necessary financing in place, Avalon intends to proceed with the necessary project engineering and process testwork to take the PEA development model to the Pre-Feasibility or Feasibility level of confidence on capital and operating cost estimates.

Sustainability and Permitting

The small environmental footprint, including low GHG emissions, and almost non-existent air emissions planned in the first stage, makes this phased development approach advantageous to the permitting process. There are no anticipated environmental impacts of concern at the project, with the mineral deposit and waste rock being non-toxic and non-acid generating, with minimal water discharge anticipated. Avalon continues to update and validate its completed 2007 environmental baseline study and the tailing management system design. The Company is planning to formally start the permitting process this summer, once sufficient engineering data and project financing are in place. Avalon is also currently working with Hydro One to determine the optimal route to deliver clean hydro-electric power to the site from one of the nearby dams on the English River.

The staged development approach is also advantageous to Avalon’s potential Indigenous partners by providing time to consider opportunities for direct participation in project development and time for individual members to obtain the necessary training for jobs at the site. Engagement is ongoing with local Indigenous communities, regulators, and local government who continue to be supportive of the project.

The technical information included in this news release has been reviewed and approved by the Company’s Vice President, Exploration, Dr. William Mercer, P. Geo (Ont), and Dave Marsh, FAusIMM (CP), Senior Vice President, Metallurgy and Technology Development, both Qualified Persons under NI 43-101.

About Avalon Advanced Materials Inc.

Avalon Advanced Materials Inc. is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology. The Company has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback, please e-mail the Company at ir@AvalonAM.com, or phone Don Bubar, President & CEO at 416-364-4938.

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements include, but are not limited to statements that the new resource estimate will be incorporated into an updated PEA now in preparation and targeted for completion by June 30, 2018, that the current model, will be the basis for the updated PEA, statements about the proposed plant production and potential capex, cash flow and flexibility, that this development model has several significant economic benefits that greatly reduce overall investment risk, that with the completion of the updated PEA and the necessary financing in place, Avalon intends to proceed with the necessary project engineering and process testwork to take the PEA development model to the Pre-Feasibility or Feasibility level of confidence on capital and operating cost estimates, that there are no anticipated environmental impacts of concern at the project and that the Company is planning to formally start the permitting process at the end of June, when engineering data and financing are available. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “potential”, “scheduled”, “anticipates”, “continues”, “expects” or “does not expect”, “is expected”, “scheduled”, “targeted”, “planned”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be” or “will not be” taken, reached or result, “will occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avalon to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. Although Avalon has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to market conditions, and the possibility of cost overruns or unanticipated costs and expenses as well as those risk factors set out in the Company’s current Annual Information Form, Management’s Discussion and Analysis and other disclosure documents available under the Company’s profile at www.SEDAR.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Such forward-looking statements have been provided for the purpose of assisting investors in understanding the Company’s plans and objectives and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking statements. Avalon does not undertake to update any forward-looking statements that are contained herein, except in accordance with applicable securities laws.

Table 1: Separation Rapids Lithium Deposit Mineral Resources Estimate as at May 22, 2018 (PZ refers to Petalite Zone and LPZ refers to Lepidolite-Petalite Zone)

PZ LPZ
Mt % Li2 O % Ta2 O5 % CsO % Rb2 O Mt % Li2 O % Ta2 O5 % CsO % Rb2 O
Measured 2.425 1.440 0.005 0.010 0.322 0.939 1.410 0.008 0.027 0.473
Indicated 3.992 1.391 0.006 0.012 0.338 1.049 1.402 0.009 0.025 0.469
Measured + Indicated 6.416 1.409 0.006 0.011 0.332 1.989 1.406 0.009 0.026 0.471
Inferred 1.308 1.351 0.007 0.017 0.342 0.483 1.346 0.008 0.020 0.427
Total PZ+LPZ
Mt % Li2 O % Ta2 O5 % CsO % Rb2 O
Measured 3.364 1.431 0.006 0.015 0.365
Indicated 5.041 1.393 0.007 0.014 0.366
Measured + Indicated 8.405 1.408 0.007 0.015 0.365
Inferred 1.791 1.349 0.007 0.018 0.365

Footnotes:

  1. This resource estimate is valid as of May 22, 2018.
  2. CIM definitions were followed for Mineral Resources.
  3. The Qualified Person for this Mineral Resource estimate is William Mercer, PhD, P.Geo. (ON).
  4. The resource estimate is based on Avalon’s drilling of 74 previous holes totalling 11,644 metres drilled between 1997 and 2017 and a further four holes totalling 1,282 metres in 2018.
  5. Drill data was organized in Maxwell DataShed and for estimation purposes was transferred to Geovia GEMS 6.8 software, wherein the block model was developed.
  6. The geological units were modeled as outlined by drill core logs.
  7. Resources were estimated by interpolating composites within a block model of 10 x 10 x 3 metre blocks oriented along the deposit strike.
  8. Grade interpolation used the Ordinary Kriging method combined with variograms and search ellipses modeled for each rock unit. For PZ unit, search ellipses of 50 x 35 x 15 m and 175 x 125 x 45 m were used for Passes 1 and 2, respectively. For LPZ unit, search ellipses of 35 x 25 x 8, 75 x 50 x 15 and 115 x 75 x 25 were used for Passes 1, 2 and 3, respectively.
  9. Measured material was defined as blocks interpolated using Passes 1 and 2, using composites from ≥ 4 drill holes and a distance ≤ 25 m to the nearest composite and additional blocks with excellent geological and grade continuity. Indicated material includes blocks interpolated with Pass 1 and 2 search ellipses, using ≥ 3 drill holes and a distance ≤ 35 m to the nearest composite and blocks with geological and grade continuity. Inferred material was defined as blocks interpolated with all Passes, composites from ≥ 2 drill holes and interpolated geological continuity up to 40 m below diamond drill holes.
  10. Two metre composites were used and no capping was necessary.
  11. The mean density of 2.65 t/m3 was used for unit 6ABC and 2.62 t/m3 for unit 6D.
  12. The cut-off grade reported in this resource estimate, 0.6% Li2O, is consistent with the previously published resource estimates by Avalon (Preliminary Economic Assessment, 2016; November 15, 2017 resource estimate).
  13. Mineral resources do not have demonstrated economic viability and their value may be materially affected by environmental, permitting, legal, title, socio-political, marketing or other issues.

Wrap Technologies Assigned Trading Symbol “WRTC”

By Wrap Technologies, Inc.

Follows Completion of $3.49 Million Self-Underwritten IPO

LAS VEGAS, NV / ACCESSWIRE / May 23, 2018 / Wrap Technologies, Inc. (OTC PINK: WRTC), an innovator of modern policing solutions, is pleased to announce that the Financial Industry Regulatory Authority (FINRA) has assigned “WRTC’ as the Company’s new ticker symbol and quotations under that symbol have commenced on the OTC Pink® Open Market.

For information on the Company please visit www.wraptechnologies.com.

In addition, the Company has applied to OTC Markets to have its shares of common stock quoted on the OTCQB® Venture Market. The Company is also processing an application to the Depository Trust Company (DTC) for its shares to become DTC eligible.

About Wrap Technologies

Wrap Technologies is an innovator of modern policing solutions. Wrap Technology premiered its hand-held BolaWrap™ 100 remote restraint solution at the International Association of Police Chiefs (IACP) October 2017 international conference.

BolaWrap is a patent pending, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to entangle an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the small but powerful BolaWrap assists law enforcement to safely and effectively control encounters.

Trademark Information: BolaWrap is a trademark of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company’s overall business, total addressable market and expectations regarding future sales and expenses. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors included in the Company’s most recent quarterly report on Form 10-Q and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Wrap Technologies Contact

Alex Barnes
800-583-262, Ext #1
alex@wraptechnologies.com

SOURCE: Wrap Technologies, Inc

ReleaseID: 500668

PreveCeutical Provides Update on Forward Stock Split

Vancouver, British Columbia–(Newsfile Corp. – May 23, 2018) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical“), announces that, further to shareholder approval of a forward stock split (the “Stock Split“) of the Company’s issued and outstanding common shares (each, a “Share“) on the basis of five new Shares for each one existing Share (see news release dated May 17, 2018), the Company’s Shares have commenced trading today on the Canadian Securities Exchange on an “ex-distribution” basis.

The record date for the Stock Split has been set at May 24, 2018. Shareholders of the Company do not need to take any action with respect to the Stock Split.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

“Stephen Van Deventer”
Chairman, CEO and President

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

ForwardLooking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including the inability of the Company to execute its proposed business plans and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.